slide1
Download
Skip this Video
Download Presentation
NASDAQ: OMRI

Loading in 2 Seconds...

play fullscreen
1 / 26

NASDAQ: OMRI - PowerPoint PPT Presentation


  • 154 Views
  • Uploaded on

Innovative Solutions for a Healthier World. Merrill Lynch 2007 Global Pharmaceutical, Biotechnology & Medical Device Conference February 6-8, 2007 Robert Taub, President & Chief Executive Officer. NASDAQ: OMRI. SAFE HARBOR STATEMENT.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' NASDAQ: OMRI' - shel


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1

Innovative Solutions for a Healthier World

Merrill Lynch2007 Global Pharmaceutical, Biotechnology & Medical Device Conference February 6-8, 2007Robert Taub, President & Chief Executive Officer

NASDAQ: OMRI

safe harbor statement
SAFE HARBOR STATEMENT
  • This presentation contains forward-looking statements. Forward-looking statements provide the company\'s current expectations or forecasts of future events. Forward-looking statements include statements about the company\'s expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘ongoing,’’ ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project’’ or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking.
  • Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. The company\'s actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the company’s filings with the SEC, including sections entitled ‘‘Risk Factors’’ and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in the company\'s prospectus as filed with the Securities and Exchange Commission on December 15, 2006 and the company’s most recent quarterly reports on Form 10-Q and its current reports on Form 8-K. Accordingly, you should not unduly rely on these forward-looking statements, which speak only as of the date of this press release.
  • Unless required by law, the company undertakes no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events. You should, however, review the factors and risks we describe in the reports the company will file from time to time with the Securities and Exchange Commission after the date of this presentation.
omrix biopharmaceuticals inc
OMRIX Biopharmaceuticals, Inc.
  • Biopharmaceutical player in protein-based biosurgery and passive immunotherapy
  • Diversified and synergistic business platforms
  • Hemostasis in surgery backed by Johnson & Johnson
  • Hyperimmunes provide upside potential

BIOSURGERY

IMMUNOTHERAPY

investment highlights
INVESTMENT HIGHLIGHTS
  • Establishing presence in growing and underpenetrated markets
    • Expanding market share with commercialized biosurgery product, Evicel; indication expansion expected in 2H07
    • 2H07 Thrombin launch is anticipated to capture market share
  • Continued growth and profitability
    • 157% product sales growth ($41.2M YTD Q306 vs. $16.0M YTD Q305)*
    • $16.7M net income in Q306 vs. net loss of $27.8M in Q305
  • Visible pipeline of near-term and medium-term product launches
    • Breakthrough biosurgery product in development addressing brisk bleeding: The Fibrin Patch
    • Three immunotherapy product candidates to address emerging viral threats
  • Long-term development, marketing & distribution partnership with Ethicon, a Johnson & Johnson company and dominant player in surgical closure and wound management, including hemostasis
  • Differentiated business model
    • Manufacturing commonalities and economies of scale between two business lines
    • Development costs financed by third parties

* Total revenues: $45.7M YTD Q306, $19.2M YTD Q305

our strategy
OUR STRATEGY

BIOSURGERY

  • Execute and expand Ethicon partnership
  • Develop new products outside of Ethicon relationship
  • Commercialize hemostasis products in new territories

IMMUNOTHERAPY

  • Three tiered strategy:
    • Launch current products in new territories
    • Commercialize product candidates
    • Rapidly respond to emerging viral threats

Achieve continued growth while maintaining financial discipline

market opportunity hemostasis
MARKET OPPORTUNITY - HEMOSTASIS

Active hemostats is fastest growing segment of surgical sealant market

$1,500 (WW)

Fibrin Sealants

&

Thrombin Products

CAGR = 10%

$650 (WW)

$1,100

Fibrin Sealants

&

Thrombin Products

Fibrin Patch

$400

2006

2015

Note: $ in millions

Source: IMS data, Company Reports and OMRIX Estimates

market shift towards active and advanced hemostats
MARKET SHIFT:TOWARDS ACTIVE AND ADVANCED HEMOSTATS
  • Passive Hemostats
  • Action: Mechanical
  • Active Hemostats
  • Action: Physiological
  • Advanced Hemostats
  • Action: Combination of mechanical and physiological

Fibrin SealantsEvicel™ / Quixil™

Gelatin/Collagen-Based

Fibrin Patch

Thrombin

Cellulose-Based

Price per procedure~$200 - $500

Price per procedureTBD

Price per procedure~$50 - $100

evicel us quixil eu liquid fibrin sealants
EVICEL (US) / QUIXIL (EU): LIQUID FIBRIN SEALANTS

Competitive Advantages

    • Ease of use
      • Ready to use in less than one minute (refrigerated)
        • No mixing or reconstitution required
      • Sprays or drips with same device tip
    • Safety
      • Human only, no bovine
      • Needle-free device
  • Product Overview
  • Used as adjunct to hemostasis in surgery
  • Only commercially available bovine-free fibrin sealant
  • Indicated for liver surgery in US; General hemostasis in EU
  • 2006 US Market: ~$100M, Growing 15% annually

Evicel Approval Timeline

2H07

1H07

1H06

Kidney Surgery Indication

PV Surgery Indication

Liver Surgery Indication

General Hemostasis Indication

thrombin stand alone
THROMBIN STAND-ALONE
  • Product Overview
  • BLA submitted on November 6, 2006
  • Designed for gradual onset of clotting
  • Component of Evicel registered as stand-alone product

2006 US Thrombin Products Market

    • >300M
  • Competitive Advantages
    • Ease of use
      • Ready to use in less than one minute (refrigerated)
        • No mixing or reconstitution required
    • Safety
      • Human only, no bovine
    • Partnered with Ethicon
      • Launch, marketing to be powered by Ethicon leadership
fibrin patch breakthrough convergence product
FIBRIN PATCH:BREAKTHROUGH CONVERGENCE PRODUCT
  • Product Overview
  • Phase 1 clinical trial commenced on December 6, 2006
  • Addressing unmet medical need – Hemostasis in severe bleeding scenarios
  • Convergence of Johnson & Johnson’s matrix with OMRIX’s biologicals
  • Global Market Opportunity
    • $400M
  • Competitive Advantages
    • Multiple development barriers to entry
    • Lack of comparable product on market or in development

“#1 project in Ethicon pipeline”

  • Dan Wildman, President Johnson & Johnson Wound Management

Biodegradable matrix

Embedded fibrin sealant biologics

johnson johnson partnership overview
JOHNSON & JOHNSON PARTNERSHIP OVERVIEW
  • Exclusive supply, distribution and development agreement
  • OMRIX receives substantial revenue share
  • Johnson & Johnson expands leadership position in hemostasis market
  • Sales & marketing
  • Development costs
  • Manufacturing
  • Regulatory submissions
  • ONE-STOP-SHOP FOR SURGICAL HEMOSTATS
beyond hemostasis market opportunities
BEYOND HEMOSTASIS: MARKET OPPORTUNITIES

OMRIX Biopharmaceuticals, Inc.

Ethicon

Other Partners

Healing

Fibrin Polymer

Internal Wound

Tissue

Engineering, Repair,

Regeneration

Adhesion

Prevention

Bleeding

Hemostasis

three marketed immunotherapy products
THREE MARKETED IMMUNOTHERAPY PRODUCTS
  • Intravenous Immunoglobulin (IVIG)
  • Currently marketed in Israel
  • Phase 3 study in US by FFF Enterprises
  • HYPERIMMUNES:
  • Provide ongoing protection, prevention and treatment against viral threats and infectious diseases
  • Vaccinia Immunoglobulin (VIG)
  • Biodefense stockpile
  • Treatment of smallpox vaccine related complications
  • Hepatitis B Immunoglobulin (HBIG)
  • For the prevention of post liver transplant Hepatitis B re-infection
  • POLYVALENT IMMUNOGLOBULIN:
upcoming milestones
UPCOMING MILESTONES

Clinical Development

Clinical Development

Phase 3

sBLA – Supplemental Biologics License Application

delivering results
DELIVERING RESULTS

190%

Increased Product Volume Drives Margin Expansion

income statement balance sheet in thousands except per share data
INCOME STATEMENT& BALANCE SHEET ($ IN THOUSANDS, EXCEPT PER SHARE DATA)

* Note: Figures include $15.3 million sales under the UK contract for VIG.

          • As of September 30, 2006
  • Cash and short term investments $40,463*
  • Total debt $1,370
  • Working capital $47,511 Total assets $76,390

* Note: Figure does not include $51.4 million in net proceeds raised from follow-on offering and exercise of over-allotment completed on December 14, 2006 and January 12, 2007, respectively.

management team
MANAGEMENT TEAM
  • Robert Taub, Founder, President and CEO
    • 30+ years pharmaceutical experience; serial entrepreneur
    • Co-Founder of Octapharma AG, a privately-held plasma fractionator
    • Monsanto; Revlon Health Care Group;Baxter International Inc.
  • Michael Burshtine, Executive Vice President, Chief Financial Officer
    • Former PricewaterhouseCoopers partner
    • Joined in 2004, has worked with OMRIX since 1995
  • Nissim Mashiach, Executive Vice President, Chief Operating Officer
    • 20 years device and biological experience
    • Joined 1998, prior management experience in leading Israeli pharmaceutical and biotech companies
  • Orgad Laub, Ph.D., Vice President, R&D Immunotherapy
    • 25 years of biotechnology experience
    • Chiron, Ares Serono and The Weizmann Institute of Science
  • Israel Nur, Ph.D., Vice President, R&D Biosurgery
    • 15 years of biosurgery experience at Octapharma and OMRIX
  • Hank Safferstein, Ph.D., JD, Vice President, Business Development
    • 15 years biotechnology and pharmaceutical experience
    • Bristol-Myers Squibb; The National Institutes of Health; Acorda Therapeutics
investment highlights1
INVESTMENT HIGHLIGHTS
  • Establishing presence in growing and underpenetrated markets
    • Expanding market share with commercialized biosurgery product, Evicel; indication expansion expected in 2H07
    • 2H07 Thrombin launch is anticipated to capture market share
  • Continued growth and profitability
    • 157% product sales growth ($41.2M YTD Q306 vs. $16.0M YTD Q305)*
    • $16.7M net income in Q306 vs. net loss of $27.8M in Q305
  • Visible pipeline of near-term and medium-term product launches
    • Breakthrough biosurgery product in development addressing brisk bleeding: The Fibrin Patch
    • Three immunotherapy product candidates to address emerging viral threats
  • Long-term development, marketing & distribution partnership with Ethicon, a Johnson & Johnson company and dominant player in surgical closure and wound management, including hemostasis
  • Differentiated business model
    • Manufacturing commonalities and economies of scale between two business lines
    • Development costs financed by third parties

* Total revenues: $45.7M YTD Q306, $19.2M YTD Q305

slide25

Innovative Solutions for a Healthier World

Merrill Lynch2007 Global Pharmaceutical, Biotechnology & Medical Device Conference February 6-8, 2007Robert Taub, President & Chief Executive Officer

NASDAQ: OMRI

fibrinogen crosslinking
FIBRINOGEN CROSSLINKING

FIBRINOGEN

D:D

D domain

E domain

Thrombin

FPA

D:D

XIIIa

g dimer

(XIIIa)

D:E

Crosslinked fibrinogen

Crosslinked fibrin

Thrombin

FPA

FIBRIN

ad